PURPOSE: The combined external beam- and high-dose rate brachytherapy (HDR-BT) of @entity263 was introduced at Kiel University in 1986. The aim of this intermediate analysis was to judge the Kiel method of @entity263 radiation treatment after ten years experience. @entity1 AND METHODS: In the past ten years 174 @entity1 with histological proven @entity263 were subjected to combined tele-/HDR-brachytherapy. Local staging in all of the cases by transrectal ultrasound, nodal staging in the majority of the cases by CT or MRI. Average age of the @entity1 was 68.2 years (44-84). According to AJCC/UICC staging T1B, T2, T3 was found in 2, 113 and 59 cases, respectively. Highly differentiated @entity5 (G1) were found in 27, moderately differentiated (G2) in 87, poorly differentiated (G3) in 60 cases. The mean follow-up was 47.1 months with the median of 51.7 months. Total prescribed dose 50 Gy on the small pelvis and 70 Gy on the prostate capsule due to the integration of two, 15 Gy each, @entity3831 in 6 weeks. RESULTS: Ten @entity1 died of @entity263 and 18 of intercurrent diseases resulting in a 5 years overall survival rate of 83% and @entity5 specific survival rate of 94%. Twenty-one @entity1 showed a clinical progression, of these 14 systemic, 5 local and 2 both systemic and local. Additional 16 @entity1 had PSA elevation only. The 5-years biochemical and/or clinical progression-free survival in the cohort was 79% and 73% for the T3 @entity5 . Side effects were 27 cases of @entity4272 / @entity1960 and 20 cases of @entity3833 / @entity2335 . CONCLUSION: The integrated HDR-BT combined with external beam radiation treatment is a method with excellent @entity5 control rates at five years superior to those of external beam treatment alone or external beam combined with @entity1496 -125 implants. This form of radiotherapy would appear to be particularly well-suited to treatment of advanced localized (T3) @entity5 .

Prostate preservation by combined external beam and HDR brachytherapy in nodal negative XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity1496 :: ('MESH:D007455', 'Chemical') :: ['iodine'] @entity263 :: ('MESH:D011471', 'Disease') :: ['localized prostate cancer', 'prostate cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity4272 :: ('MESH:D011349', 'Disease') :: ['proctitis'] @entity3831 :: ('MESH:C537907', 'Disease') :: ['HDR-brachytherapy fractions'] @entity1960 :: ('MESH:D003092', 'Disease') :: ['colitis'] @entity3833 :: ('MESH:D053159', 'Disease') :: ['dysuria'] @entity2335 :: ('MESH:D003556', 'Disease') :: ['cystitis']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
